Comparison of direct oral anticoagulants and low-molecular-weight heparins in cancer patients with nonvalvular atrial fibrillation: insights from a single-center experience

Clicks: 2
ID: 323414
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #250 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background/Introduction Atrial fibrillation (AF) is frequently encountered in patients with cancer and poses challenges for anticoagulant management. Cancer itself promotes a prothrombotic state, while anticancer therapies further elevate thromboembolic risk and paradoxically predispose to bleeding. Patients with both cancer and AF face a four- to seven-fold higher risk of venous thromboembolism (VTE) and a two-fold higher bleeding risk compared to those with AF alone. While direct oral anticoagulants (DOACs) have been shown to effectively reduce stroke risk in non-valvular AF (NVAF), cancer patients were largely excluded from randomized trials. In practice, concerns about drug interactions and bleeding often lead physicians to prefer low molecular weight heparin (LMWH), yet data comparing these agents in NVAF are scarce. Purpose The present study was conducted to compare clinical outcomes associated with DOACs and LMWH in individuals with active malignancy and NVAF. We hypothesized that this study would provide valuable insights to guide clinical practice, support clinical decision-making, and promote timely initiation of anticoagulant therapy. Methods Data from patients with active cancer who received LMWAH or DOAC for NVAF were retrospectively screened. Efficacy, safety, and survival outcomes were analyzed. Results The study enrolled 222 patients, of whom 25.7% received LMWH and 74.3% received DOACs. Cancer stage, type, and treatment were comparable between groups. The DOAC group had higher CHA2DS2-VA (3.13 ± 1.21 vs. 2.42 ± 1.33; p < 0.001) and HAS-BLED scores (2.13 ± 0.83 vs. 1.84 ± 0.79; p = 0.022). The primary composite endpoint occurred more frequently in the LMWH group (17.5% vs. 12.1%; log-rank p = 0.036). Myocardial infarction was significantly higher in the LMWH group (8.8% vs. 1.8%; log-rank p=0.003), while rates of ischemic stroke (3.5% vs. 6.7%; log-rank p=0.927) and VTE (5.3% vs. 4.8%; p = 0.537) were similar. Any bleeding (17.5% vs. 13.3%; log-rank p=0.039) and major bleeding (7.0% vs. 1.8%; log-rank p=0.010) were more frequent with LMWH, whereas clinically relevant non-major bleeding was comparable (10.5% vs. 11.5%; log-rank p=0.359). All-cause mortality was significantly higher in the LMWH group (75.4% vs. 49.1%; log-rank p < 0.001), and LMWH use independently predicted mortality (HR = 2.14; 95% CI 1.45–3.17; p < 0.001). Conclusions Although unmeasured confounders such as drug adherence and selection bias—since LMWH may have been preferentially prescribed to frail patients—cannot be excluded due to the retrospective design, DOACs appear to be more effective and safer than LMWH in cancer patients with AF.Figure 1 Figure 2
Reference Key
openalex_W7172315356 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors I Ceren, Y Z Sener, K Gocer, H G Firat, K Ohtaroglu Tokdil, F Yildiz, F Bozduman Habip, E Acikgoz, O Ates, M Gerede Uludag, E Eroglu Buyukoner
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.139
URL
https://doi.org/10.1093/eurheartjsupp/suag097.139
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.